Elon Musk’s tunneling startup, aptly-named The Boring Company, has taken a step towards its proposed loop system in the East Coast. In an announcement on Wednesday, the Transportation Department stated that the project had completed its environmental assessment, a draft of which will be available for public comment for the next 45 days.
It has four chambers, blood vessels and it beats — sort of.
In a first, scientists have 3D printed a heart using human tissue. Though the heart is much smaller than a human’s (it’s only the size of a rabbit’s), and there’s still a long way to go until it functions like a normal heart, the proof-of-concept experiment could eventually lead to personalized organs or tissues that could be used in the human body, according to a study published Monday (April 15) in the journal Advanced Science.
Viela Bio today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for the Company’s anti-CD19 monoclonal antibody inebilizumab, an investigational monotherapy for neuromyelitis optica spectrum disorder (NMOSD). NMOSD is a rare, life-threatening autoimmune disease affecting the central nervous system.
If asked “What’s the most talent competitive city in the U.S.?” few Americans would name the top of our global list: Washington, D.C. (1). Often considered to be a (political) quagmire, the greater metropolitan area actually has a tremendous amount to offer. With an excellent environmental quality, major universities, an impressive number of physicians in the area and, of course, the presence of international global organisations, the greater Washington area provides a complete environment for talent competitiveness.
A nascent project launched by the Health and Human Services Department aims to spur innovation and help solve an expensive health crisis plaguing millions of Americans: kidney disease.
Developers hope it will one day be used as a model not only for introducing innovators to government, but for addressing other high-cost diseases.
The BioHealth Capital Region (BHCR) is rapidly becoming an industry hub for companies that are developing next-generation therapeutics that focus on personalized and regenerative medicine for the treatment and potential cure of unmet medical needs. Autolus, Inc., a CAR T-cell therapy company, and REGENXBIO, a gene therapy company focused therapies for rare diseases, are two examples of emerging leaders in the personalized medicine field making their imprint on the region.
Children’s National today announced a $30 million gift from the United Arab Emirates (UAE), marking a major milestone in the creation of its new Research & Innovation Campus. The gift will help drive pediatric discoveries that save and improve the lives of children in the Washington, D.C. region and around the world.
Scientists at Tel Aviv University (TAU) have printed the world’s first 3D vascularized engineered heart using a patient’s own cells and biological materials. Their findings appear (“Printing of Personalized Thick and Perfusable Cardiac Patches and Hearts”) in Advanced Science.
In honor of the new JLABS @ Washington, DC – a 32,000 square foot facility located on the new Children’s National Research and Innovation Campus from Johnson & Johnson Innovation, LLC in partnership with Children’s National Health System[1] (“Children’s National”) – Johnson & Johnson Innovation – JLABS announces the JLABS @ Washington, DC Children’s QuickFire Challenge.
Visionaries within the fields of pediatric oncology, pediatric surgery and influenza are invited to submit innovative ideas for a total of up to $150,000 in grant funding*; one year of residency at JLABS @ Washington, DC with the use of a bench, workstation, and access to the JLABS @ Washington, DC community; and mentorship from experts at the Johnson & Johnson Family of Companies.
Emergent BioSolutions Inc. (NYSE:EBS) today announced results from the interim analysis of its Phase 2 clinical study evaluating the safety and immunogenicity of the company’s chikungunya virus virus-like particle (CHIKV-VLP) vaccine candidate across a series of dosing regimens. The interim analysis has shown that with a single dose administered, up to 98% of study participants produced a neutralizing antibody response against the chikungunya virus (CHIKV) by Day 7. Further, the immune response was shown to be persistent through the six-month visit, including in the one-dose regimen.
